About Leucine-rich repeats and immunoglobulin-like domains protein 2
Leucine-rich repeats and immunoglobulin-like domains protein 2 (LRIG2) is a protein
from Homo sapiens identified by UniProt accession
O94898, 1065 residues long.
MolForge cross-references it against 0 known binders and
67 disease associations.
Target properties
| Protein name | Leucine-rich repeats and immunoglobulin-like domains protein 2 |
|---|
| UniProt accession | O94898 |
|---|
| Gene | LRIG2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1065 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (67)
Diseases linked to this target (Open Targets).
- Ochoa syndrome · score 0.75
- congenital anomaly of kidney and urinary tract · score 0.37
- Global developmental delay · score 0.34
- neurodegenerative disease · score 0.31
- neoplasm · score 0.10
- neutrophil count · score 0.09
- glioblastoma multiforme · score 0.09
- glioblastoma · score 0.08
- non-small cell lung carcinoma · score 0.08
- osteosarcoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O94898-F1 | alphafold | PREDICTED | 74.48 | — |
Amino-acid sequence (1065 residues)
MAPAPLGVPE EQLLGCRSRV LSRLLFIAQT ALLLLPAAGA GLCPAPCSCR IPLLDCSRRK LPAPSWRALS GLLPPDTAIL DFSHNRLSNW NISLESQTLQ EVKMNYNELT EIPYFGEPTS NITLLSLVHN IIPEINAQAL QFYPALESLD LSSNIISEIK TSSFPRMQLK YLNLSNNRIT TLEAGCFDNL SSSLLVVKLN RNRMSMIPPK IFKLPHLQFL ELKRNRIKIV EGLTFQGLDS LRSLKMQRNG ISKLKDGAFF GLNNMEELEL EHNNLTRVNK GWLYGLRMLQ QLYVSQNAIE RISPDAWEFC QRLSELDLSY NQLTRLDESA FVGLSLLERL NLGDNRVTHI ADGVFRFLSN LQTLDLRNNE ISWAIEDASE AFAGLTSLTK LILQGNQIKS ITKKAFIGLE SLEHLDLNNN AIMSIQENAF SQTHLKELIL NTSSLLCDCH LKWLLQWLVD NNFQHSVNVS CAHPEWLAGQ SILNVDLKDF VCDDFLKPQI RTHPETIIAL RGMNVTLTCT AVSSSDSPMS TVWRKDSEIL YDVDTENFVR YWQQAGEALE YTSILHLFNV NFTDEGKYQC IVTNHFGSNY SQKAKLTVNE MPSFLKTPMD LTIRTGAMAR LECAAEGHPA PQISWQKDGG TDFPAARERR MHVMPEDDVF FIANVKIEDM GIYSCMAQNT AGGLSANASL TVLETPSFIR PLEDKTVTRG ETAVLQCIAG GSPAPRLNWT KDDGPLLVTE RHFFAAANQL LIIVDAGLED AGKYTCIMSN TLGTERGHIY LNVISSPNCD SSQSSIGHED DGWTTVGIVI IVVVCCVVGT SLIWVIVIYH MRRKNEDYSI TNTEELNLPA DIPSYLSSQG TLSEPQEGYS NSEAGSHQQL MPPANGYIHK GTDGGTGTRV ICSDCYDNAN IYSRTREYCP YTYIAEEDVL DQTLSSLMVQ MPKETYLVHP PQDTTALESL IPSANREPSA FPTNHERISE KKLPSTQMSG ETLQRPVWNI NRELGLPHPP FSQQPVHESP QLHQNEGLAG REPDCSASSM SCHRLQDHAF DFSRTRNIQD GSEGT
Explore Leucine-rich repeats and immunoglobulin-like domains protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets